if the genetically engineered macromolecules , e.g. , lymphokines , and other new modalities , e.g. , killer lymphocytes , as well as low molecular weight cytotoxic agents , are to fulfill their clinical promise , methods must be developed to overcome these physiological barriers .
C0024297
lymphokines
C0024264
lymphocytes